within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A04A_AntiemeticsAndAntinauseants.A04AA01_Ondansetron;

model Ondansetron_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 7.222222222222223e-06,
    adminDuration = 600,
    adminMass = 8 / 1000000,
    adminCount = 1,
    Vd = 0.075,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.106,
    k12 = 1.352777777777778e-05,
    k21 = 1.352777777777778e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ondansetron_1</td></tr><tr><td>ATC code:</td><td>A04AA01_1</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>8</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>75</td><td>L</td></tr>
    <tr><td>clearance:</td><td>26</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ondansetron is a selective serotonin 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting caused by cancer chemotherapy, radiotherapy, and surgery. It is approved and widely used internationally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following intravenous administration in healthy adults; parameters reflect standard IV dosing.</p><h4>References</h4><ol><li><p>Mondick, JT, et al., &amp; Hoke, JF (2010). Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months. <i>European journal of clinical pharmacology</i> 66(1) 77–86. DOI:<a href=\"https://doi.org/10.1007/s00228-009-0730-8\">10.1007/s00228-009-0730-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19798490/\">https://pubmed.ncbi.nlm.nih.gov/19798490</a></p></li><li><p>Sotelo, CK, et al., &amp; Zersen, KM (2022). Pharmacokinetics and anti-nausea effects of intravenous ondansetron in hospitalized dogs exhibiting clinical signs of nausea. <i>Journal of veterinary pharmacology and therapeutics</i> 45(6) 508–515. DOI:<a href=\"https://doi.org/10.1111/jvp.13087\">10.1111/jvp.13087</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35899472/\">https://pubmed.ncbi.nlm.nih.gov/35899472</a></p></li><li><p>Chiang, MD, et al., &amp; Haroutounian, S (2021). Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans. <i>British journal of clinical pharmacology</i> 87(2) 516–526. DOI:<a href=\"https://doi.org/10.1111/bcp.14412\">10.1111/bcp.14412</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32495990/\">https://pubmed.ncbi.nlm.nih.gov/32495990</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A04AA01_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ondansetron_1;
